ArticleMolecular neurobiology2025
Renal Denervation Improves Myocardial Mitochondrial Dysfunction and Myocardial Fibrosis by Inhibiting the NE/KLF15/renalase Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Loss of KLF15 expression characterizes proximal tubule injury in cisplatin-induced acute kidney injury: A multi-omics study.Current research in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Renal denervation (RDN) reduces cardiac sympathetic nerve activity maintained by arterial hypertension. This study aimed to investigate whether RDN affects myocardial mitochondrial oxidative stress and myocardial fibrosis through norepinephrine (NE)/Kruppel-like factor 15 (KLF15)/renalase (RNLS) pathway. The impact of RDN on myocardial remodeling was assessed in rats subjected to transverse aortic coarctation (TAC) surgery. To explore the mechanism by which NE influences mitochondrial oxidative stress and fibrosis in AC16 cardiomyocytes, we intervened with KLF15 and RNLS. The molecular mechanism underlying the role of RDN in TAC-induced myocardial remodeling was achieved through intraperitoneal injection of NE and adeno-associated virus to knock down KLF15 and RNLS. Echocardiography showed that RDN increased left ventricular ejection fraction and fractional shortening in TAC rats, while decreasing left ventricular end-systolic diameter. RDN decreased the myocardial infarction size, myocardial tissue injury, and fibrosis; decreased serum NE level; increased RNLS level; and promoted KLF15 and RNLS expression in cardiac tissue in TAC rats. NE prevented RDN effects on TAC rats. Further results showed that RDN improved myocardial remodeling in TAC rats by upregulating RNLS. NE promoted mitochondrial oxidative stress and fibrosis in cardiomyocytes by inhibiting RNLS. Mechanically, NE aggravated mitochondrial oxidative stress and fibrosis of cardiomyocytes by inhibiting KLF15 to downregulate RNLS. Moreover, RDN improved myocardial remodeling in TAC rats by upregulating KLF15. Our results implicated that RDN improved mitochondrial oxidative stress and myocardial fibrosis by inhibiting the NE/KLF15/RNLS pathway. Our findings demonstrated that the NE/KLF15/RNLS axis is a molecular strategy for RDN treatment of myocardial fibrosis.
Indexed as
Identifiers
40739379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.